跳到正文
openFDA 已分级药品召回执法报告·· 12 天前精选AI 评分71

FDA 执法报告 D-0165-2027 收录 Hikma 环丙沙星片亚硝胺超限的 Class II 自愿召回

FDA drug enforcement D-0165-2027: Hikma Pharmaceuticals USA INC. — CGMP Deviations: N-nitroso-ciprofloxacin results above the FDA recommended interim control limit.

AI 导读

FDA 执法报告 D-0165-2027 收录 Hikma Pharmaceuticals USA 对环丙沙星片 USP 500 mg 的 Class II 自愿召回,原因列为 CGMP 偏差,N-亚硝基环丙沙星结果超出 FDA 建议的临时控制限。

推荐理由

记录列出环丙沙星片因 N-亚硝基环丙沙星超出 FDA 建议临时控制限而由企业自愿召回,便于比对同类杂质的控制与分级信息。

正文 · 原文

FDA drug recall enforcement report — D-0165-2027

Report issued: 2026-11-11. This is the enforcement report date, not the recall initiation date.

Scope: one classified drug product recall record; event_id may group multiple products. Unclassified records without recall numbers are outside this stream. This record is not a press release or a new enforcement finding.

The openFDA dataset is updated weekly. Report status is not a live recall status and must not be used to track the recall lifecycle. Other dates below retain their named meanings.

Complete official product record (including openFDA harmonized identifiers):

{

"address_1": "1809 Wilson Rd",

"address_2": "",

"center_classification_date": "20261103",

"city": "Columbus",

"classification": "Class II",

"code_info": "Lot# CB496A; Exp. 12/31/2026 Lot# CB497A; Exp. 12/31/2026 Lot# CB498A; Exp. 12/31/2026",

"country": "United States",

"distribution_pattern": "US Nationwide",

"event_id": "100142",

"initial_firm_notification": "Letter",

"more_code_info": "",

"openfda": {

"application_number": [

"ANDA076558"

],

"brand_name": [

"CIPROFLOXACIN"

],

"generic_name": [

"CIPROFLOXACIN"

],

"is_original_packager": [

true

],

"manufacturer_name": [

"Hikma Pharmaceuticals USA Inc."

],

"package_ndc": [

"0143-9927-01",

"0143-9927-05",

"0143-9927-30",

"0143-9928-01",

"0143-9928-05",

"0143-9928-30",

"0143-9929-01",

"0143-9929-50"

],

"product_ndc": [

"0143-9928",

"0143-9927",

"0143-9929"

],

"product_type": [

"HUMAN PRESCRIPTION DRUG"

],

"route": [

"ORAL"

],

"rxcui": [

"197511",

"197512",

"309309"

],

"spl_id": [

"7caf3140-173f-4afa-8066-fb22953646c2"

],

"spl_set_id": [

"3b3d22dc-df09-4910-8c9b-1204eeedbd68"

],

"substance_name": [

"CIPROFLOXACIN HYDROCHLORIDE"

],

"unii": [

"4BA73M5E37"

]

},

"postal_code": "43228-9579",

"product_description": "Ciprofloxacin Tablets, USP, 500 mg, 100-count bottle, Rx Only, Manufactured by: Hikma Pharmaceuticals, P.O. Box 182400, Amman, 11118-Jordan, Distributed by: Hikma Pharmaceuticals USA Inc. Berkely Heights, NJ 07922, NDC 0143-9928-01",

"product_quantity": "29,085 bottles",

"product_type": "Drugs",

"reason_for_recall": "CGMP Deviations: N-nitroso-ciprofloxacin results above the FDA recommended interim control limit.",

"recall_initiation_date": "20261020",

"recall_number": "D-0165-2027",

"recalling_firm": "Hikma Pharmaceuticals USA INC.",

"report_date": "20261111",

"state": "OH",

"status": "Ongoing",

"voluntary_mandated": "Voluntary: Firm initiated"

}

来源:openFDA 已分级药品召回执法报告 · api.fda.gov